iBio to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Update on Tuesday, February 16, 2021

NEXT STORY
Revive Therapeutics Receives Receipt for Final Short-Form Prospectus for Previously Announced $20 Million Bought Deal Public Offering
PREV STORY
Bolt Biotherapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Glycotope Selects CrownBio as a Preclinical Development Partner to Advance Their Immunotherapeutic Pipeline

SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of ...

author_avatar
NASDAQ Market News

VBI Vaccines Announces Second Quarter 2018 Financial Results and Provides Corporate Update

-- Pivotal Phase 3 program for Sci-B-Vac® Hepatitis B vaccine continues to advance towards ...

author_avatar
NASDAQ Market News

Chembio Diagnostics, Inc. Announces Upsizing And Pricing Of Public Offering Of Common Stock

MEDFORD, N.Y., July 29, 2016 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader ...

author_avatar
NASDAQ Market News